LUMEN THERAPEUTICS - Key Persons
Job Titles:
- Member of the Scientific Advisory Board
- Cardiologist
Dr. Gersh is a Cardiologist at the Mayo Clinic. Dr. Gersh, M.B., Ch.B., D.Phil, received his M.B., Ch.B. in 1965 from the University of Cape Town, South Africa, and his D.Phil degree from Oxford University, England, as a Rhodes Scholar from 1967 to 1970. From 1978 to 1993, Dr. Gersh was at Mayo Clinic where he served as Director of the Coronary Care Units with additional commitments to invasive and noninvasive electrophysiology and cardiac pacing. From 1993 to 1998, Dr. Gersh was the William Proctor Harvey Teaching Professor of Cardiology and Chief of Cardiology at Georgetown University Medical Center. He returned to Mayo Clinic in 1998 where he holds the rank of Professor of Medicine and Vice-Chair of Academic Affairs and Faculty Development. He is a Past-Chairman of the Council of Clinical Cardiology of the American Heart Association, has served on of the Board of Trustees of the American College of Cardiology, and served as Chairman of the Annual Scientific Sessions of the American College of Cardiology in 1992. He currently serves on the Planning and Steering Committees and Data Safety Monitoring Boards of several large NIH-sponsored and other randomized trials and the Advisory Boards of many organization and foundations committed to translational research and academic development including the Advisory Board of the Reynolds Foundation.
Job Titles:
- Chief
- Director
- Founder
- Member of the Scientific Advisory Board
- Professor
Dr. Fathman is Professor of Medicine and Chief of the Division of Immunology and Rheumatology at Stanford University School of Medicine and is also director of the Center for Clinical Immunology at Stanford (CCIS). Dr. Fathman received his M.D. from Washington University in St. Louis and did his residency training at Dartmouth Affiliated Hospitals and a fellowship in immunology and rheumatology at Stanford University before completing an additional 4 years of basic immunology research at the NIH and Basel . He then joined the faculty at the Mayo Clinic in 1977 and was recruited to Stanford University in 1981. There he continues his seminal work on T cell activation and regulation in association with autoimmune diseases. Dr. Fathman has published over 250 articles in his field and is a member of many professional organizations, including the American Association of Immunologists and the Association of American Physicians, and is founding Chairman of the Federation of Clinical Immunology Societies (FOCIS). He was a co-founder of Cetus Immune, Immulogic and CellGate, and has served on the SAB of multiple companies.
Job Titles:
- Director
- Founder
- Member of the Scientific Advisory Board
- Professor of Medicine and Pathology of the Stanford University School of Medicine
Dr. Engleman is Professor of Medicine and Pathology of the Stanford University School of Medicine and Director of the Stanford Blood Center. He received his Bachelor's degree from Harvard University and his M.D. from Columbia University School of Medicine. He completed three postgraduate training programs and now runs a research laboratory at Stanford focused on the discovery and development of novel immunotherapeutic approaches to cancer and autoimmune diseases. He co-founded Cetus Immune, Genelabs, National Medical Audit, Dendreon, and CellGate. Dr. Engleman is also a Member of BioAsia Investments, a venture investment company investing in life sciences companies, and serves on the board of directors of several private biopharmaceutical companies.
Job Titles:
- Member of the Scientific Advisory Board
- Director of the Institute of Molecular Medicine
Dr. Murad is Director of the Institute of Molecular Medicine (U of Texas-Houston). He attended DePauw University, 1954-58, B.A. degree; Case Western Reserve University, 1958-65, M.D. and Ph.D. degrees; internship and residency in Internal Medicine at Massachusetts General Hospital, 1965-67; clinical research associate and staff fellow, National Heart, Lung and Blood Institute, 1967-70; Associate Professor and Professor Departments of Medicine and Pharmacology, University of Virginia, 1970-81, Director of the Clinical Research Center 1971-81 and the Division of Clinical Pharmacology 1973-81; Professor Departments of Medicine and Pharmacology, Stanford University 1981-88 and Chief of Medicine Palo Alto Veterans Medical Center; VP of Discovery Research and VP R&D Abbott Laboratories 1988-93; President & CEO Molecular Geriatrics 1993-96; Professor and Chairman Dept. Integrative Biology and Pharmacology, U. Texas Houston 1997-Present and Director Institute of Molecular Medicine 1999-present. He is the recipient of many honorary degrees and awards, most notable are Ciba Award 1988, Lasker Awards for Basic Medical Research 1996 and the Nobel Prize in Physiology or Medicine 1998. He is a member of the National Academy of Sciences, the American Academy of Arts and Science and the Institute of Medicine. His research interests are in the areas of nitric oxide, cyclic GMP and cellular signaling in vascular biology and other systems.
Job Titles:
- Member of the Scientific Advisory Board
John P. Cooke, MD, Ph.D., is Professor of Medicine and Director of the NHLBI funded Program in Vascular Biology and Medicine at Stanford. He has published over 250 articles on topics of vascular medicine and biology as well as a textbook in vascular medicine. He is a nationally recognized figure in endothelial biology, and his research focuses on endothelial biology, specifically the role of NO synthase in angiogenesis and atherosclerosis, as well as a novel angiogenic pathway discovered in the Cooke Lab and mediated by an endothelial nACh receptor. Dr. Cooke has served on numerous national and international committees that deal with cardiovascular diseases, including those of the American Heart Association, American College of Cardiology and the National Heart, Lung and Blood Institute. He has special expertise in development of agents for peripheral arterial disease, and is a member of the Vascular Trialists, a group of clinician-investigators with particular interest in formulating and executing trials for testing novel therapies for PAD.
Job Titles:
- Member of the Scientific Advisory Board
Dr. Rothbard was a co-founder of CellGate and served as CellGate's Chief Scientific Officer, overseeing exploratory research efforts and investigating new directions for CellGate's technology development. Earlier, Dr. Rothbard was a Senior Director of ImmuLogic Corporation and the head of the laboratory of molecular immunology at the Imperial Cancer Research Fund in London. He received his Ph.D. in organic chemistry from Columbia University and completed a postdoctoral fellowship at The Rockefeller University. He has over 100 publications in the fields of chemistry biochemistry and immunology. Dr. Rothbard is an inventor of the use of oligo-L-arginines for the prevention of stenosis.
Mike Danaher is a partner in the law firm of Wilson Sonsini Goodrich & Rosati, Michael Danaher works with private and public emerging growth companies in the life sciences and other high technology industries. He handles general corporate matters and transactions, including private financings, public offerings, mergers and acquisitions. Mr. Danaher graduated from Yale College in 1975 and from Stanford Law School in 1980.
Job Titles:
- Director
- Founder
- VP Biopharmaceutical Development
Dr. McGrane has sixteen years of experience in the research and development of pharmaceutical agents. He joined CellGate as its first hire in chemistry and assumed the lead role in development efforts at CellGate, with primary oversight of the outsourcing of the preclinical, CMC and clinical functions. From late 1994 through 1998 Dr. McGrane worked first for Pfizer (Groton, CT) and then for Roche Bioscience (Palo Alto, CA). His duties included the development of scalable processes for the manufacture of molecules of pharmaceutical interest. Previous to this, Dr. McGrane spent two years as a postdoctoral fellow at Stanford University where he played a vital role in designing and executing a total synthesis of the chemotherapeutic agent Taxol®. He received his PhD in chemistry from Montana State University and his B.S. degree in chemistry from the South Dakota School of Mines and Technology. Dr. McGrane is a Registered Patent Agent and one of Lumen's founders.
Job Titles:
- Member of the Scientific Advisory Board
- Chairman of the Department of Cardiothoracic Surgery
Dr. Robbins is Chair of the Department of Cardiothoracic Surgery at Stanford University School of Medicine, where he has been a member of the faculty since 1993. He currently serves as Director of the Heart, Heart/Lung and Lung Transplant Program, Co-Director Cardiac Center, and is the Director of the Cardiothoracic Transplantation Laboratory. Dr. Robbins received his B.S. degree from Millsap's College in 1979 and M.D. from the University of Mississippi Medical Center in 1983. He completed his general surgery training at the University of Mississippi Medical Center in 1989 and his Cardiothoracic Surgery training at Stanford University School of Medicine in 1992.
Dr. Robbins was a Pediatric Fellow of Cardiothoracic Surgery at Emory University, Atlanta GA and Royal Children's Hospital in Melbourne, Australia. He was also a Clinical Associate, Surgery Branch NHLBI at the National Institute of Health in Bethesda, MD. In addition, Dr. Robbins is the Guest Editor for Circulation, a manuscript reviewer for a number of periodicals including New England Journal of Medicine Annals of Thoracic Surgery, and is on the editorial board for the Journal of Thoracic and Cardiovascular Surgery. Dr. Robbins is certified by the American Board of Surgery and the American Board of Thoracic Surgery. He serves on the Scientific Advisory Boards for several companies. His current research interests include transplant immunology, stem cell therapy and tissue engineering.
Job Titles:
- Member of the Scientific Advisory Board
Dr. Stertzer received his MD from the NYU School of Medicine and interned in surgery at the University of California Hospitals, San Francisco. He served as Assistant Resident in Medicine at NYU and later as Chief Medical Resident at NYU Division of Bellevue Hospital. He had a fellowship at NYU Hospital in Cardiovascular Disease.
His numerous academic and hospital appointments include Attending Cardiologist at NYU School of Medicine 1965-1983, Chief of the Hemodynamics Laboratory at Lenox Hill Hospital New York from 1971-1983, and Director of Medical Research, San Francisco Heart Institute, Seton Medical Center, Daly City, CA, 1983-1992. He is currently the Director of Experimental Angioplasty, Clinical Professor of Medicine and Associate Director of International Medical Services at Stanford University School of Medicine.
Dr. Stertzer pioneered the subspecialty of Interventional Cardiology and was the first to perform a coronary angioplasty in the United States. He has written, lectured and taught extensively about such new technologies as: 1. Treatment of acute heart attacks with angioplasty, 2. High speed Rotational Atherectomy, 3. Stent treatment of Coronary Disease, 4.Pacemaker Therapy, and 5. Drug eluting devices for coronary restenosis.
He and his staff are currently working on other leading edge technologies in genomics and coronary intervention.